Open Access
Review
Targeting Inflammation to Control Tissue Fibrosis
Weihua Song1
, Wu Sun2
, Zilong Wang3
, Kelvin Yi Chong Teo2, 4, 5
, Chui Ming Gemmy Cheung2, 4, 5
, Xiaomeng Wang4, 5, 6, *
Author Information
Submitted: 17 Nov 2022 | Accepted: 19 Nov 2022 | Published: 21 Dec 2022
Abstract
Remodeling of the extracellular matrix (ECM) is an essential process in host defense against pathogens and tissue repair following injury. However, aberrant inflammatory responses could disturb ECM homeostasis leading to progressive disruption in tissue architecture and organ function. Fibrosis is the common outcome of a wide range of diseases, especially chronic inflammatory disorders, and represents the leading cause of morbidity and mortality globally. This review provides the current understanding of the pathogenesis of fibrosis, with particular emphasis on the role of inflammation in this process and the translational potential of targeting inflammation as a strategy to control fibrotic progression.
Keywords
References
1.
Duffield J.S.; Lupher M.; Thannickal V.J.; et al. Host responses in tissue repair and fibrosis. Annu. Rev. Pathol., 2013, 8, 241-276.
2.
Suarez-Carmona M.; Lesage J.; Cataldo D.; et al. EMT and inflammation: inseparable actors of cancer progression. Mol. Oncol., 2017, 11(7): 805-823.
3.
Cho J. G.; Lee A.; Chang W.; et al. Endothelial to Mesenchymal Transition Represents a Key Link in the Interaction between Inflammation and Endothelial Dysfunction. Front. Immunol., 2018, 9, 294.
4.
Meng X. M.; Wang S.; Huang X. R.; et al. Inflammatory macrophages can transdifferentiate into myofibroblasts during renal fibrosis. Cell Death Dis., 2016, 7(12): e2495.
5.
Little K.; Llorián-Salvador M.; Tang M.; et al. Macrophage to myofibroblast transition contributes to subretinal fibrosis secondary to neovascular age-related macular degeneration. J. Neuroinflammation, 2020, 17(1): 355.
6.
Medzhitov R. Inflammation 2010: new adventures of an old flame. Cell, 2010, 140(6): 771-776, doi:10.1016/j.cell.2010.03.006.
7.
Wynn T. A. Cellular and molecular mechanisms of fibrosis. J. Pathol., 2008, 18(3): 199-210, doi:10.1002/path.2277.
8.
Li M.O.; Flavell R.A. Contextual regulation of inflammation: a duet by transforming growth factor-beta and interleukin-10. Immunity 2008, 28(4): 468-476, doi:10.1016/j.immuni.2008.03.003 .
9.
Li M.O.; Sanjabi S.; Flavell R.A. Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity, 2006, 25(3): 455-471, doi:10.1016/j.immuni.2006.07.011.
10.
Marie J.C.; Liggitt D.; Rudensky A.Y. Cellular mechanisms of fatal early-onset autoimmunity in mice with the T cell-specific targeting of transforming growth factor-beta receptor. Immunity, 2006, 25 (3): 441-454, doi:10.1016/j.immuni.2006.07.012.
11.
Li M.O.; Flavell R.A. TGF-beta: a master of all T cell trades. Cell, 2008, 134(3): 392-404, doi:10.1016/j.cell.2008.07.025.
12.
Zhou L.; Lopes J.E.; Chong M.M.; et al. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature, 2008, 453(7192): 236-240, doi:10.1038/nature06878.
13.
Filippi C.M.; Juedes A.E.; Oldham J.E.; et al. Transforming growth factor-beta suppresses the activation of CD8+ T-cells when naive but promotes their survival and function once antigen experienced: a two-faced impact on autoimmunity. Diabetes, 2008, 57(10): 2684-2692, doi:10.2337/db08-0609.
14.
Laouar Y.; Sutterwala F.S.; Gorelik L.; et al. Transforming growth factor-beta controls T helper type 1 cell development through regulation of natural killer cell interferon-gamma. Nat. Immunol., 2005, 6(6): 600-607, doi:10.1038/ni1197.
15.
Laouar Y.; Town T.; Jeng D.; et al. TGF-beta signaling in dendritic cells is a prerequisite for the control of autoimmune encephalomyelitis. Proc. Natl. Acad. Sci., 2008, 105(31): 10865-10870, doi:10.1073/pnas.0805058105.
16.
Frangogiannis N. Transforming growth factor-beta in tissue fibrosis. J. Exp. Med., 2020, 217(3): e20190103, doi:10.1084/jem.20190103.
17.
Miettinen P.J.; Ebner R.; Lopez A.R.; et al. TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J. Cell Biol., 1994, 127(6 Pt 2): 2021-2036, doi:10.1083/jcb.127.6.2021.
18.
Derynck R.; Zhang Y. E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature, 2003, 425(6958): 577-584, doi:10.1038/nature02006.
19.
Wendt M.K.; Allington T.M.; SchiemannW. P. Mechanisms of the epithelial-mesenchymal transition by TGF-beta. Future Oncol., 2009, 5(8): 1145-1168, doi:10.2217/fon.09.90.
20.
Kriz W.; Kaissling B.; Le Hir M. Epithelial-mesenchymal transition (EMT) in kidney fibrosis: fact or fantasy? J. Clin. Invest. 2011, 214 (2): 468-474, doi:10.1172/jci44595.
21.
Meng F.; Li J.; Yang X.; et al. Role of Smad3 signaling in the epithelialmesenchymal transition of the lens epithelium following injury. Int. J. Mol. Med., 2018, 42(2): 851-860, doi:10.3892/ijmm.2018.3662.
22.
Zeisberg M.; Hanai J.; Sugimoto H.; et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat. Med., 2003 9(7): 964-968, doi:10.1038/nm888.
23.
Wang J.; Hu K.; Cai X.; et al. Targeting PI3K/AKT signaling for treatment of idiopathic pulmonary fibrosis. Acta Pharm. Sin. B 2022, 12(1): 18-32, doi:10.1016/j.apsb.2021.07.023.
24.
Dolivo D.M.; Larson S.A.; Dominko T. Crosstalk between mitogen-activated protein kinase inhibitors and transforming growth factor-beta signaling results in variable activation of human dermal fibroblasts. Int J Mol Med 2019, 43(1): 325-335, doi:10.3892/ijmm.2018.3949.
25.
Ma J.; van der Zon G.; Sanchez-Duffhues G.; et al. TGF-beta-mediated Endothelial to Mesenchymal Transition (EndMT) and the Functional Assessment of EndMT Effectors using CRISPR/Cas9 Gene Editing. J. Vis. Exp., 2021, 168, doi:10.3791/62198.
26.
Song S.; Zhang R.; Cao W.; et al . Foxm1 is a critical driver of TGF-beta-induced EndMT in endothelial cells through Smad2/3 and binds to the Snail promoter. J. Cell Physiol., 2019, 234(6): 9052-9064, doi:10.1002/jcp.27583.
27.
Ihn H. Pathogenesis of fibrosis: role of TGF-beta and CTGF. Curr. Opin. Rheumatol., 2002, 14(6): 681-685, doi:10.1097/00002281-200211000-00009.
28.
Abreu J.G.; Ketpura N.I.; Reversade B.; et al. Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat. Cell Biol., 2002, 4(8): 599-604, doi:10.1038/ncb826.
29.
Idriss H.T.; Naismith J. H. TNF alpha and the TNF receptor superfamily: structure-function relationship(s). Microsc. Res. Tech., 2000, 50(3): 184-195, doi:10.1002/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H.
30.
Bradley J.R. TNF-mediated inflammatory disease. J. Pathol., 2008, 214(2): 149-160, doi:10.1002/path.2287.
31.
Montrucchio G.; Lupia E.; Battaglia E.; et al. Tumor necrosis factor alpha-induced angiogenesis depends on in situ platelet-activating factor biosynthesis. J. Exp. Med., 1994, 180(1): 377-382, doi:10.1084/jem.180.1.377.
32.
Hammam O.; Mahmoud O.; Zahran M.; et al. A Possible Role for TNF-alpha in Coordinating Inflammation and Angiogenesis in Chronic Liver Disease and Hepatocellular Carcinoma. Gastrointest. Cancer Res., 2013, 6(4): 107-114.
33.
Pandey A.; Shao H.; Marks R.M.; et al. Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF-alpha-induced angiogenesis. Science, 1995, 268(5210): 567-569, doi:10.1126/science.7536959.
34.
Wang X.; Lin Y. Tumor necrosis factor and cancer, buddies or foes? Acta. Pharmacol. Sin., 2008,29 (11): 1275-1288, doi:10.1111/j.1745-7254.2008.00889.x.
35.
Theiss A.L.; Simmons J.G.; Jobin C.; et al. Tumor necrosis factor (TNF) alpha increases collagen accumulation and proliferation in intestinal myofibroblasts via TNF receptor 2. J. Biol. Chem., 2005 280(43): 36099-36109, doi:10.1074/jbc.M505291200.
36.
Mederacke I.; Hsu C.C.; Troeger J.S.; et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat. Commun., 2013, 4, 2823, doi:10.1038/ncomms3823.
37.
TraceyK. J.; Cerami A. Tumor necrosis factor: an updated review of its biology. Crit. Care Med., 1993, 21(10 Suppl): S415-422.
38.
Pradere J. P.; Kluwe J.; De Minicis S.; et al. Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice. Hepatology, 2013, 58(4): 1461-1473, doi:10.1002/hep.26429.
39.
Bates R.C.; Mercurio A.M. Tumor necrosis factor-alpha stimulates the epithelial-to-mesenchymal transition of human colonic organoids. Mol. Biol. Cell, 2003, 14(5): 1790-1800, doi:10.1091/mbc.e02-09-0583.
40.
Liao S.J.; Luo J.; Li D.; et al. TGF-beta1 and TNF-alpha synergistically induce epithelial to mesenchymal transition of breast cancer cells by enhancing TAK1 activation. J. Cell Commun. Signal, 2019, 13(3): 369-380, doi:10.1007/s12079-019-00508-8.
41.
Dong W.; Sun S.; Cao X.; et al. Exposure to TNFalpha combined with TGFbeta induces carcinogenesis in vitro via NF-kappaB/Twist axis. Oncol. Rep. 2017, 37(3): 1873-1882, doi:10.3892/or.2017.5369.
42.
Knittel T.; Mehde M.; Kobold D.; et al. Expression patterns of matrix metalloproteinases and their inhibitors in parenchymal and non-parenchymal cells of rat liver: regulation by TNF-alpha and TGF-beta1. J. Hepatol., 1999, 30(1): 48-60, doi:10.1016/s0168-8278(99)80007-5.
43.
Solis-Herruzo J.A.; Brenner D.A.; Chojkier M. Tumor necrosis factor alpha inhibits collagen gene transcription and collagen synthesis in cultured human fibroblasts. J. Biol. Chem., 1988, 263(12): 5841-5845.
44.
Mauviel A.; Lapiere J.C.; Halcin C.; et al. Differential cytokine regulation of type I and type VII collagen gene expression in cultured human dermal fibroblasts. J. Biol. Chem., 1994, 269(1): 25-28.
45.
Verrecchia F.; Wagner E.F.; Mauviel A. Distinct involvement of the Jun-N-terminal kinase and NF-kappaB pathways in the repression of the human COL1A2 gene by TNF-alpha. EMBO Rep., 2002, 3(11): 1069-1074, doi:10.1093/embo-reports/kvf219.
46.
Hernandez-Munoz I.; de la Torre P.; Sánchez-Alcázar J. A.; et al. Tumor necrosis factor alpha inhibits collagen alpha 1(I) gene expression in rat hepatic stellate cells through a G protein. Gastroenterology, 1997, 113(2): 625-640, doi:10.1053/gast.1997.v113.pm9247485.
47.
Iraburu M.J.; Domínguez-Rosales J. A.; Fontana L.; et al. Tumor necrosis factor alpha down-regulates expression of the alpha1(I) collagen gene in rat hepatic stellate cells through a p20C/EBPbeta- and C/EBPdelta-dependent mechanism. Hepatology, 2000, 31(5): 1086-1093, doi:10.1053/he.2000.5981.
48.
Verrecchia F.; Tacheau C.; Wagner E.F.; et al. A central role for the JNK pathway in mediating the antagonistic activity of pro-inflammatory cytokines against transforming growth factor-beta-driven SMAD3/4-specific gene expression. J. Biol. Chem., 2003, 278(3): 1585-1593, doi:10.1074/jbc.M206927200.
49.
Verrecchia F.; Mauviel A. TGF-beta and TNF-alpha: antagonistic cytokines controlling type I collagen gene expression. Cell Signal, 2004, 16(8): 873-880, doi:10.1016/j.cellsig.2004.02.007 .
50.
Yamane K.; Ihn H.; Asano Y.; et al. Antagonistic effects of TNF-alpha on TGF-beta signaling through down-regulation of TGF-beta receptor type II in human dermal fibroblasts. J. Immunol., 2003, 171(7): 3855-3862, doi:10.4049/jimmunol.171.7.3855.
51.
Fickenscher H.; Hör S.; Küpers H.; et al. The interleukin-10 family of cytokines. Trends Immunol., 2002, 23(2): 89-96, doi:10.1016/s1471-4906(01)02149-4.
52.
Richmond J.; Tuzova M.; Cruikshank W.; et al. Regulation of cellular processes by interleukin-16 in homeostasis and cancer. J. Cell. Physiol., 2014, 229(2): 139-147, doi:10.1002/jcp.24441.
53.
Dinarello C. A. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol. Rev., 2018, 281(1): 8-27, doi:10.1111/imr.12621.
54.
Sims J.E.; Smith D.E. The IL-1 family: regulators of immunity. Nat. Rev. Immunol., 2010, 10(2): 89-102, doi:10.1038/nri2691.
55.
Borthwick L.A. The IL-1 cytokine family and its role in inflammation and fibrosis in the lung. Semin. Immunopathol., 2016, 38(4): 517-534, doi:10.1007/s00281-016-0559-z.
56.
Gasse P.; Mary C.; Guenon I.; et al. IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice. J. Clin. Invest., 2007, 117(12): 3786-3799, doi:10.1172/JCI32285.
57.
Pauwels N.S.; Bracke K.R.; Dupont L.; et al. Role of IL-1alpha and the Nlrp3/caspase-1/IL-1beta axis in cigarette smoke-induced pulmonary inflammation and COPD. Eur. Respir. J., 2011, 38(5): 1019-1028, doi:10.1183/09031936.00158110.
58.
Hogg J.C.; Chu F.; Utokaparch S.; et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med., 2004, 350(26): 2645-2653, doi:10.1056/NEJMoa032158.
59.
Wilson M.S.; Madala S.K.; Ramalingam T.; et al. Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent. J. Exp. Med., 2010, 207(3): 535-552, doi:10.1084/jem.20092121 .
60.
Kolb M.; Margetts P.J.; Anthony D.C.; et al. Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis. J. Clin. Invest., 2001, 107(12): 1529-1536, doi:10.1172/JCI12568.
61.
Guo J.; Gu N.; Chen J.; et al. Neutralization of interleukin-1 beta attenuates silica-induced lung inflammation and fibrosis in C57BL/6 mice. Arch. Toxicol., 2013, 87(11): 1963-1973, doi:10.1007/s00204-013-1063-z.
62.
Hill C.; Jones M.G.; Davies D.E.; et al. Epithelial-mesenchymal transition contributes to pulmonary fibrosis via aberrant epithelial/fibroblastic cross-talk. J. Lung Health Dis., 2019, 3(2): 31-35.
63.
Li R.; Ong S.L.; Tran L.M.; et al. Chronic IL-1beta-induced inflammation regulates epithelial-to-mesenchymal transition memory phenotypes via epigenetic modifications in non-small cell lung cancer. Sci. Rep., 2020, 10(1): 377, doi:10.1038/s41598-019-57285-y.
64.
Masola V.; Carraro A.; Granata S.; et al. In vitro effects of interleukin (IL)-1 beta inhibition on the epithelial-to-mesenchymal transition (EMT) of renal tubular and hepatic stellate cells. J. Transl. Med., 2019, 17(1): 12, doi:10.1186/s12967-019-1770-1.
65.
Gieling R.G.; Wallace K.; Han Y. P. Interleukin-1 participates in the progression from liver injury to fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol., 2009, 296(6): G1324-1331, doi:10.1152/ajpgi.90564.2008.
66.
Hirano T.; Yasukawa K.; Harada H.; et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature, 1986, 324(6092): 73-76, doi:10.1038/324073a0.
67.
Rodriguez-Bayona B.; Ramos-Amaya A.; Lopez-Blanco R.; et al. STAT-3 activation by differential cytokines is critical for human in vivo-generated plasma cell survival and Ig secretion. J. Immunol., 2013, 191(10): 4996-5004, doi:10.4049/jimmunol.1301559.
68.
Kopf M.; Baumann H.; Freer G.; et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature, 1994, 368(6469): 339-342, doi:10.1038/368339a0.
69.
Ramsay A.J.; Husband A.J.; Ramshaw I.A.; et al. The role of interleukin-6 in mucosal IgA antibody responses in vivo. Science, 1994, 264(5158): 561-563, doi:10.1126/science.8160012.
70.
Tsukamoto H.; Fujieda K.; Hirayama M.; et al. Soluble IL6R Expressed by Myeloid Cells Reduces Tumor-Specific Th1 Differentiation and Drives Tumor Progression. Cancer Res., 2017, 77(9): 2279-2291, doi:10.1158/0008-5472.CAN-16-2446.
71.
Rincon M.; Anguita J.; Nakamura T.; et al. Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4+ T cells. J. Exp. Med., 1997, 185(3): 461-469, doi:10.1084/jem.185.3.461.
72.
Johnson B.Z.; Stevenson A.W.; Prele C.M.; et al. The Role of IL-6 in Skin Fibrosis and Cutaneous Wound Healing. Biomedicines, 2020, 8(5): doi:10.3390/biomedicines8050101.
73.
Pedroza M.; Alcorn J.L.; Galas D.; et al. Interleukin-6 contributes to inflammation and remodeling in a model of adenosine mediated lung injury. PLoS One, 2011, 6(7): e22667, doi:10.1371/journal.pone.0022667.
74.
Sato S.; Hasegawa M.; Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J. Dermatol. Sci., 2001, 27(2): 140-146, doi:10.1016/s0923-1811(01)00128-1.
75.
Migita K.; Abiru S.; Maeda Y.; et al. Serum levels of interleukin-6 and its soluble receptors in patients with hepatitis C virus infection. Hum. Immunol. 2006, 67(1-2): 27-32, doi:10.1016/j.humimm.2006.02.025.
76.
Zhong H.; Belardinelli L.; Maa T.; et al. Synergy between A2B adenosine receptors and hypoxia in activating human lung fibroblasts. Am. J. Respir. Cell Mol. Biol., 2005, 32(1): 2-8, doi:10.1165/rcmb.2004-0103OC.
77.
Dai Y.; Zhang W.; Wen J.; et al. A2B adenosine receptor-mediated induction of IL-6 promotes CKD. J. Am. Soc. Nephrol., 2011, 22(5): 890-901, doi:10.1681/ASN.2010080890.
78.
Melendez G.C.; McLarty J.L.; Levick S.P.; et al. Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension, 2010, 56(2): 225-231, doi:10.1161/HYPERTENSIONAHA.109.148635.
79.
Tanaka T.; Narazaki M.; Kishimoto T. Therapeutic targeting of the interleukin-6 receptor. Annu. Rev. Pharmacol. Toxicol., 2012, 52, 199-219, doi:10.1146/annurev-pharmtox-010611-134715.
80.
Fielding C.A.; Jones G.W.; McLoughlin R.M. ; et al. Interleukin-6 signaling drives fibrosis in unresolved inflammation. Immunity, 2014, 40(1): 40-50, doi:10.1016/j.immuni.2013.10.022.
81.
O’Donoghue R.J.; Knight D.A.; Richards C.D.; et al. Genetic partitioning of interleukin-6 signalling in mice dissociates Stat3 from Smad3-mediated lung fibrosis. EMBO Mol. Med., 2012, 4(9): 939-951, doi:10.1002/emmm.201100604.
82.
Shima Y.; Kuwahara Y.; Murota H.; et al. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology (Oxford), 2010, 49(12): 2408-2412, doi:10.1093/rheumatology/keq275.
83.
Barata J.T.; Durum S.K.; Seddon B. Flip the coin: IL-7 and IL-7R in health and disease. Nat. Immunol., 2019, 20(12): 1584-1593, doi:10.1038/s41590-019-0479-x.
84.
Dubinett S.M.; Huang M.; Dhanani S.; et al. Down-regulation of macrophage transforming growth factor-beta messenger RNA expression by IL-7. J. Immunol., 1993, 151(12): 6670-6680.
85.
Huang M.; Sharma S.; Zhu L.X.; et al. IL-7 inhibits fibroblast TGF-beta production and signaling in pulmonary fibrosis. J. Clin. Invest., 2002, 109(7): 931-937, doi:10.1172/JCI14685.
86.
Hsieh P.F.; Liu S.F.; Lee T.C.; et al. The role of IL-7 in renal proximal tubule epithelial cells fibrosis. Mol. Immunol., 2012, 50(1-2): 74-82, doi:10.1016/j.molimm.2011.12.004.
87.
Jimenez-Sousa M.A.; Gómez-Moreno A.Z.; Pineda-Tenor D.; et al. The IL7RA rs6897932 polymorphism is associated with progression of liver fibrosis in patients with chronic hepatitis C: Repeated measurements design. PLoS One, 2018, 13(5): e0197115, doi:10.1371/journal.pone.0197115.
88.
Li B.; Li Y.; Li S.; et al. Circ_MTM1 knockdown inhibits the progression of HBV-related liver fibrosis via regulating IL7R expression through targeting miR-122-5p. Am. J. Transl. Res., 2022, 14(4): 2199-2211.
89.
Zlotnik A.; Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity, 2000, 12(2): 121-127, doi:10.1016/s1074-7613(00)80165-x.
90.
Cyster J. G. Leukocyte migration: scent of the T zone. Curr. Biol., 2000, 10(1): R30-33, doi:10.1016/s0960-9822(99)00253-5.
91.
Bonecchi R.; Galliera E.; Borroni E.M.; et al. Chemokines and chemokine receptors: an overview. Front. Biosci., (Landmark Ed) 2009, 14(2): 540-551, doi:10.2741/3261.
92.
Baggiolini M.; Moser B.; Clark-Lewis I. Interleukin-8 and related chemotactic cytokines. The Giles Filley Lecture. Chest, 1994, 105(3): 95S-98S, doi:10.1378/chest.105.3_supplement.95s .
93.
Luster A.D.; Weinshank R.L.; Feinman R.; et al. Molecular and biochemical characterization of a novel gamma-interferon-inducible protein. J. Biol. Chem., 1988, 263(24): 12036-12043.
94.
Yang L.; Herrera J.; Gilbertsen A.; et al. IL-8 mediates idiopathic pulmonary fibrosis mesenchymal progenitor cell fibrogenicity. Am. J. Physiol. Lung Cell Mol. Physiol., 2018, 314(1): L127-L136, doi:10.1152/ajplung.00200.2017.
95.
Carre P.C.; et al. Increased expression of the interleukin-8 gene by alveolar macrophages in idiopathic pulmonary fibrosis. A potential mechanism for the recruitment and activation of neutrophils in lung fibrosis. J. Clin. Invest., 1991, 88(6): 1802-1810, doi:10.1172/JCI115501.
96.
Lee J.S.; Shin J.H.; Choi B. S. Serum levels of IL-8 and ICAM-1 as biomarkers for progressive massive fibrosis in coal workers' pneumoconiosis. J. Korean Med. Sci., 2015, 30(2): 140-144, doi:10.3346/jkms.2015.30.2.140.
97.
Zimmermann H.W.; Seidler S.; Gassler N.; et al. Interleukin-8 is activated in patients with chronic liver diseases and associated with hepatic macrophage accumulation in human liver fibrosis. PLoS One, 2011, 6(6): e21381, doi:10.1371/journal.pone.0021381.
98.
Dai Y.; Dean T.P.; Church M.K.; et al. Desensitisation of neutrophil responses by systemic interleukin 8 in cystic fibrosis. Thorax., 1994, 49(9): 867-871, doi:10.1136/thx.49.9.867 .
99.
Brysse A.; Mestdagt M.; Polette M.; et al. Regulation of CXCL8/IL-8 expression by zonula occludens-1 in human breast cancer cells. Mol. Cancer Res., 2012, 10(1): 121-132, doi:10.1158/1541-7786.MCR-11-0180.
100.
Zeremski M.; Petrovic L.M.; Chiriboga L.; et al. Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology, 2008, 48(5): 1440-1450, doi:10.1002/hep.22500.
101.
Hintermann E.; Bayer M.; Pfeilschifter J.M.; et al. CXCL10 promotes liver fibrosis by prevention of NK cell mediated hepatic stellate cell inactivation. J. Autoimmun., 2010, 35(4): 424-435, doi:10.1016/j.jaut.2010.09.003.
102.
von Hundelshausen P.; Koenen R.R.; Sack M.; et al. Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. Blood, 2005, 105(3): 924-930, doi:10.1182/blood-2004-06-2475.
103.
Strieter R.M.; Gomperts B.N.; Keane M.P. The role of CXC chemokines in pulmonary fibrosis. J. Clin. Invest., 2007, 117 (3): 549-556, doi:10.1172/JCI30562.
104.
Burdick M.D.; Murray L. A.; Keane M. P.; et al. CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling. Am. J. Respir. Crit. Care Med., 2005, 171(3): 261-268, doi:10.1164/rccm.200409-1164OC.
105.
Tager A.M.; Kradin R.L.; LaCamera P.; et al. Inhibition of pulmonary fibrosis by the chemokine IP-10/CXCL10. Am. J. Respir. Cell Mol. Biol., 2004, 31(4): 395-404, doi:10.1165/rcmb.2004-0175OC.
106.
Holt A.P.; Haughton E.L.; Lalor P.F.; et al. Liver myofibroblasts regulate infiltration and positioning of lymphocytes in human liver. Gastroenterology, 2009, 136(2): 705-714, doi:10.1053/j.gastro.2008.10.020.
107.
Bonacchi A.; Petrai I.; Defranco R.M.; et al. The chemokine CCL21 modulates lymphocyte recruitment and fibrosis in chronic hepatitis C. Gastroenterology, 2003, 125(4): 1060-1076, doi:10.1016/s0016-5085(03)01194-6.
108.
Nellen A.; Heinrichs D.; Berres M.L.; et al. Interference with oligomerization and glycosaminoglycan binding of the chemokine CCL5 improves experimental liver injury. PLoS One, 2012, 7(5): e36614, doi:10.1371/journal.pone.0036614.
109.
Capelli A.; Di Stefano A.; Gnemmi I.; et al. CCR5 expression and CC chemokine levels in idiopathic pulmonary fibrosis. Eur. Respir. J., 2005, 25(4): 701-707, doi:10.1183/09031936.05.00082604.
110.
Moore B.B.; Kolodsick J.E.; Thannickal V.J.; et al. CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. Am. J. Pathol., 2005, 166(3): 675-684, doi:10.1016/S0002-9440(10)62289-4.
111.
Osterholzer J.J.; Olszewski M.A.; Murdock B.J.; et al. Implicating exudate macrophages and Ly-6C(high) monocytes in CCR2-dependent lung fibrosis following gene-targeted alveolar injury. J. Immunol., 2013, 190(7): 3447-3457, doi:10.4049/jimmunol.1200604.
112.
Osterholzer J.J.; Christensen P.J.; Lama V.; et al. PAI-1 promotes the accumulation of exudate macrophages and worsens pulmonary fibrosis following type II alveolar epithelial cell injury. J. Pathol., 2012, 228(2): 170-180, doi:10.1002/path.3992.
113.
Raghu G.; Martinez F.J.; Brown K.K.; et al. CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab. Eur. Respir. J. 2015, 46(6): 1740-1750, doi:10.1183/13993003.01558-2014.
114.
Pierce E.M.; Carpenter K.; Jakubzick C.; et al. Idiopathic pulmonary fibrosis fibroblasts migrate and proliferate to CC chemokine ligand 21. Eur. Respir. J., 2007, 29(6): 1082-1093, doi:10.1183/09031936.00122806.
115.
Pierce E.M.; Carpenter K.; Jakubzick C.; et al. Therapeutic targeting of CC ligand 21 or CC chemokine receptor 7 abrogates pulmonary fibrosis induced by the adoptive transfer of human pulmonary fibroblasts to immunodeficient mice. Am. J. Pathol., 2007, 170(4): 1152-1164, doi:10.2353/ajpath.2007.060649.
116.
Pei G.; Yao Y.; Yang Q.; et al. Lymphangiogenesis in kidney and lymph node mediates renal inflammation and fibrosis. Sci. Adv., 2019, 5(6): eaaw5075, doi:10.1126/sciadv.aaw5075 .
117.
Nakayama Y.; Bromberg J.S. Lymphotoxin-beta receptor blockade induces inflammation and fibrosis in tolerized cardiac allografts. Am. J. Transplant, 2012, 12(9): 2322-2334, doi:10.1111/j.1600-6143.2012.04090.x.
118.
Wada T.; Sakai N.; Matsushima K.; et al. Fibrocytes: a new insight into kidney fibrosis. Kidney Int., 2007, 72(3): 269-273, doi:10.1038/sj.ki.5002325.
119.
Baggiolini M. Chemokines in pathology and medicine. J. Intern. Med., 2001, 250(2): 91-104, doi:10.1046/j.1365-2796.2001.00867.x.
120.
Abe R.; Donnelly S.C.; Peng T.; et al. Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J. Immunol., 2001, 166(12): 7556-7562, doi:10.4049/jimmunol.166.12.7556.
121.
Wynn T.A.; Vannella K. M. Macrophages in tissue repair, regeneration, and fibrosis. Immunity, 2016, 44(3): 450-462, doi:10.1016/j.immuni.2016.02.015.
122.
Xie T.; Wang Y.; Deng N.; et al. Single-Cell Deconvolution of Fibroblast Heterogeneity in Mouse Pulmonary Fibrosis. Cell Rep., 2018, 22(13): 3625-3640, doi:10.1016/j.celrep.2018.03.010.
123.
Peyser R.; MacDonnell S.; Gao Y.; et al. Defining the Activated Fibroblast Population in Lung Fibrosis Using Single-Cell Sequencing. Am. J. Respir. Cell Mol. Biol., 2019, 61(1): 74-85, doi:10.1165/rcmb.2018-0313OC.
Issue
Volume 1, Issue 1How to Cite
Song, W., Sun, W., Wang, Z., Teo, K. Y. C., Cheung, C. M. G., & Wang, X. (2022). Targeting Inflammation to Control Tissue Fibrosis. International Journal of Drug Discovery and Pharmacology, 1(1), 6. https://doi.org/10.53941/ijddp.v1i1.206
RIS
BibTex
Copyright & License
Xiaomeng Wang
This work is licensed under a This work is licensed under a Creative Commons Attribution 4.0 International License.